Company intelligence / Profile preview

Imbioray

Hangzhou, Zhejiang Sheng, Chinapitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

Imbioray is advancing a pipeline of off-the-shelf, allogeneic CAR-NK and NK engager therapies targeting cancer. Lead assets IBR‑822, IBR‑733, and IBR854 are in Phase 1 clinical trials for various hematologic malignancies and solid tumors. The company has received IND approval for additional programs such as IBR900 targeting B-cell lymphoma. Recent funding rounds support clinical advancement and GMP manufacturing expansion.

Therapeutic areas: OncologyHematology
Modalities: CAR-NK cell therapyCell therapyNon-genetically modified CAR-NK cell therapyNK cell engager cell therapy
Industry: Biotech

Drug pipeline

4 assets

IBR854

3 more assets in the full pipeline.

Request access →

Partnerships

T-Capital served as financial advisor in Series A financing round

Beyond the preview

Go deeper on Imbioray.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imbioray.

Explore the full profile